Demographics of the whole cohort, responders, and nonresponders.
| Characteristics | Whole Group, n = 30 | Responders, n = 10 | Nonresponders, n = 16 |
|---|---|---|---|
| Women, % | 76.7 | 70 | 81.3 |
| Age, yrs, mean (range) | 51.8 (32–70) | 55.6 (37–66) | 49.8 (32–70) |
| Duration RA, yrs | 7.7 (0.75–21) | 4.6 (0.75–18) | 7.8 (0.75–21) |
| Rheumatoid nodules, % | 16.7 | 0 | 18.8 |
| Radiographic erosions, % | 56.7 | 40 | 56.3 |
| Rheumatoid factor-positive, % | 86.7 | 90 | 93.8 |
| ACPA-positive, % | 92.9 | 100 | 87.5 |
| MTX dose (median, mg/wk) | 20 (10–20) | 20 (15–20) | 20 (10–20) |
| Duration MTX, mo | 39.5 (6–144) | 10.5 (6–96) | 30 (7–144) |
| Duration on dose MTX at entry, mo | 7 (1–106) | 6.5 (1–84) | 10.5 (3–106) |
| NSAID, % | 55.3 | 40 | 56.3 |
| Another DMARD, % | 56.7 | 50 | 62.5 |
| Prednisone, % | 43.3 | 60 | 37.5 |
RA: rheumatoid arthritis; ACPA: anticitrullinated peptide antibodies; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs.